The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).
 
Danny Rischin
Research Funding - Genentech/Roche; Merck; Threshold Pharmaceuticals
 
Michael J. Boyer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim
 
Christina E. Brzezniak
No Relationships to Disclose
 
A. Dimitrios Colevas
Stock and Other Ownership Interests - Gilead Sciences; Pharmacyclics
Research Funding - Bristol-Myers Squibb; Curis; Genentech
 
Robert Charles Doebele
Honoraria - AstraZeneca; Clovis Oncology; Loxo; OxOnc; Pfizer
Consulting or Advisory Role - Array BioPharma; Lilly; Loxo; OxOnc; Pfizer; Pfizer
Research Funding - Abbott Molecular; Loxo; Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Licensing Fees for Biologic Material from Ariad (Inst); Licensing Fees for Biologic Material from Blueprint Medicines (Inst); Licensing Fees for Biologic Material from Chugai (Inst); Licensing Fees for Biologic Materials from GVKbio; Licensing Fees for Biologic Materials from Loxo Oncology (Inst); Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495
Travel, Accommodations, Expenses - Ignyta
 
Jill Gilbert
No Relationships to Disclose
 
Barbara Gitlitz
Consulting or Advisory Role - Clovis Oncology
Speakers' Bureau - Genentech; Lilly
Research Funding - Astex Pharmaceuticals; AstraZeneca; Clovis Oncology; Novartis; Xcovery
 
Saad A. Khan
Research Funding - Bayer/Onyx (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Threshold Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Novartis
 
Ranee Mehra
Employment - GlaxoSmithKline (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - Genentech
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Tanguy Y. Seiwert
Honoraria - Amgen; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Merck; Merck Serono
Research Funding - Boehringer Ingelheim (Inst); Genentech/Roche (Inst)
 
Stew Kroll
Employment - Threshold Pharmaceuticals
Stock and Other Ownership Interests - Threshold Pharmaceuticals
 
Tillman E. Pearce
Employment - Threshold Pharmaceuticals
Stock and Other Ownership Interests - Threshold Pharmaceuticals
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Genentech; Perthera